Table 5 Therapeutic antitumor effects of various engineered extracellular vehicles (EVs)
From: Application of engineered extracellular vesicles for targeted tumor therapy
Source of EVs | EV cargos | Loading approach | Type of cancer | Function | References |
|---|---|---|---|---|---|
HEK293T cells | siRNA | Membrane-anchoring | Prostate cancer | Enhanced EV tumor targeting and inhibition of prostate cancer growth | [213] |
HepG2 cells | miR-31 and miR-451 | Electroporation | Hepatocellular carcinoma | Inhibition of tumor cell proliferation and migration | [214] |
Panc02 cells | Nanoscale metabolic precursors | Click chemistry | Pancreatic cancer | Improving the tumor targeting of EV drug delivery systems | [215] |
LNCaP PC-3 cells | PTX | Incubation | Prostate cancer | Improving chemotherapeutic drug delivery efficiency and enhancing cytotoxic effects | [134] |
Macrophage cells | DOX, PTX | Electroporation/sonication | Lung cancer | Improving chemotherapy drug delivery efficiency to inhibit tumor growth | [91] |
Mesenchymal stem cells | PLK-1 siRNA | Electroporation | Bladder cancer | Improving the targeting of EVs to tumor cells | [216] |
Ovarian cancer | DOX | Electroporation | Ovarian cancer | Improving chemotherapy drug delivery efficiency to inhibit tumor growth | [217] |
Red blood cells | Cas9 mRNA | Electroporation/incubation | Breast cancer | Improving the targeting of EVs to tumor cells and reducing adverse effects | [144] |